Tobacco Use in Your Diabetic Patients: The Clinical Case for Active Intervention

The numbers are unambiguous. India carries an estimated 89 million adults with diabetes — the second-largest burden globally — while simultaneously sustaining approximately 100 million cigarette smokers and a further 200 million smokeless tobacco users. As of 2024, smoking prevalence among Indian adult males stands at 16.7%, nearly double the global average. In clinical practice, these populations overlap extensively, yet the tobacco-diabetes intersection continues to receive less systematic attention than either condition commands individually.

Among newly diagnosed Type 2 diabetes patients in India, a study across 5,080 patients found that 21.2% carried smoking or tobacco use as a major cardiovascular risk factor at the time of first diagnosis. Nearly 61% of newly diagnosed patients were classified as "very high risk" for atherosclerotic cardiovascular disease (ASCVD) from the moment of diagnosis — and for the subset who smoke, the ASCVD risk clock has been running considerably longer.

The gender dimension is particularly pronounced in India. Male diabetic patients exhibit significantly higher rates of smoking and alcohol consumption — both established risk factors — alongside markedly poorer glycaemic control and elevated cardiovascular mortality compared to female diabetic patients. The Indian male diabetic smoker is not a niche subgroup; he is the modal patient in many general practice and diabetology settings across the country.

Understanding the clinical risk requires understanding the mechanisms. Cigarette smoke does not simply coexist with diabetes — it actively worsens every dimension of its pathophysiology through multiple overlapping pathways.

The dose-dependent relationship between smoking and glycaemic control is now well-established. The Fukuoka Diabetes Registry study of 2,490 Japanese male T2DM patients demonstrated that HbA1c levels increased progressively with both the number of cigarettes smoked per day and cumulative pack-years — a graded relationship that persisted after controlling for diet, exercise, alcohol consumption, and BMI. Conversely, HbA1c decreased linearly with years since quitting, suggesting a recoverable and time-dependent benefit from cessation.

Beyond glycaemic control, the interaction between smoking and diabetes substantially accelerates end-organ damage across the classical complication profile. The mechanisms vary by organ system, but the directional effect is consistent: smoking worsens each complication type, and the compounding of two independent risk processes — hyperglycaemia and tobacco toxicity — produces outcomes that are considerably worse than either alone.

Despite the weight of evidence, tobacco cessation remains inconsistently addressed in diabetes consultations across India. There are structural and practical reasons for this, and acknowledging them honestly is necessary before proposing solutions.

Consultation time constraints are significant. In most Indian public sector and private general practice settings, the average diabetes consultation is brief. The clinical agenda is already crowded — glycaemic review, medication adjustment, blood pressure, lipid management, foot screening, eye referral. Adding a structured tobacco cessation conversation requires time that many physicians feel they do not have.

Cessation infrastructure is underdeveloped. In many parts of India, there is no ready referral pathway for smoking cessation support. A physician who advises cessation may be unable to refer the patient anywhere for follow-up, pharmacotherapy, or behavioural support. This can create a sense of futility that discourages the conversation from beginning at all.

Patient awareness is low. Research from Kerala's diabetes clinics explicitly documented a lack of patient awareness regarding the specific linkages between smoking and diabetes complications. Patients frequently know that smoking is generally harmful, but do not understand that it is actively worsening their blood sugar control, increasing their insulin requirements, and accelerating kidney and nerve damage.

Dependence is underestimated. Among Indian tobacco users, moderate-to-high nicotine dependence is found in 60–86% of smokers. Cessation is not a matter of simple motivation; it is the management of a dependency condition. Physicians who approach it as a lifestyle choice rather than a clinical dependency issue are less likely to deploy the pharmacological and behavioural tools that actually improve outcomes.

The most robustly studied cessation framework in the Indian diabetic context is the 5As — a structured, time-efficient approach that has demonstrated efficacy in randomised trials conducted specifically in South Indian diabetes clinics.

A pilot RCT in Kerala enrolled 224 adult diabetic smokers from two diabetes clinics. Patients receiving the full 5As intervention from a trained non-doctor health professional, in addition to physician advice, had an odds ratio of 8.4 (95% CI: 4.1–17.1) for quitting at six months, compared to patients receiving physician advice alone. Even among heavy smokers, the odds of quitting were similar. The finding that non-doctor health professionals can deliver effective cessation counselling is particularly relevant in the Indian setting, where physician time is scarce.

Not all diabetic smokers present the same readiness or clinical context. The following typologies may assist in calibrating the consultation approach.

The concept of harm reduction in tobacco medicine is not new. The clinical literature increasingly supports a pragmatic position: for patients not yet ready or able to achieve full cessation, reducing the toxic burden of each cigarette is a clinically defensible interim goal. This is particularly relevant in the Indian context, where cessation support infrastructure is limited, dependence levels are high, and many patients will not achieve immediate abstinence regardless of clinical advice.

Harm reduction in this context means reducing the patient's exposure to the specific compounds in cigarette smoke that are most damaging to the diabetic system — chiefly tar (which drives inflammation and worsens insulin resistance), carbon monoxide (which impairs oxygenation in already compromised vascular beds), and carbonyls such as formaldehyde, acrolein, and crotonaldehyde (which generate oxidative stress, damage endothelium, and accelerate microvascular complications).

The evidence is sufficient. Tobacco use in diabetic patients substantially increases all-cause mortality, cardiovascular mortality, and the rate of microvascular complication progression. Cessation produces a clinically meaningful improvement in HbA1c, independent of other interventions. In Indian diabetes clinics, where the co-prevalence of smoking and diabetes is high and cessation support is underdeveloped, the physician's role in initiating and sustaining this conversation is uniquely important.

The conversation does not need to be long. It does not need to resolve in a single consultation. What it needs to be is consistent — raised at every visit, documented, and adapted to the patient's current readiness. The Kerala trial demonstrated that even brief interventions from non-physician healthcare workers significantly improve quit rates in this population. The evidence supports deploying any trained person in the clinical pathway to have this conversation.

For patients who will not quit today, harm reduction is a legitimate clinical complement, not a concession. Meeting patients where they are — with accurate information about their specific risks and practical options for reducing immediate harm — is consistent with the principles of patient-centred care. It keeps the clinical relationship intact and the door to cessation open.

The diabetic smoker in your consulting room is carrying a compounded risk that the current trajectory of their disease does not fully account for. Raising it is not an obligation that sits outside the diabetes consultation. It is the diabetes consultation.